Company

Lumeda was formed in 2020 to commercialize a therapeutic solution based on an innovation in photodynamic therapy (PDT) demonstrated by Roswell Park Comprehensive Cancer Center- a globally recognized center of excellence in this technology. Lumeda has deep roots in photonics technology through its founders that when combined with the scientific and clinical expertise of our partners at Roswell Park, has resulted in a breakthrough therapeutic platform called DigiLum™ that presents a new innovative approach to treating abdominal and thoracic cancers.

DigiLum™ is currently under clinical evaluation as an adjuvant therapy in treating patients with advanced lung cancer with pleural disease, and patients with advanced colorectal cancer with recurrent or T4 tumors undergoing surgical resection. DigiLum™ presents a new paradigm in the administration and precision of photodynamic therapy that improves both the patient and provider experience in providing a safe, effective, and more tolerable therapy free of toxicities and side effects.

 

 

Founders and Advisors

Image

Justin D. Blasberg MD, MPH, FACS 

Member, Lumeda Scientific Advisory Board         

Associate Professor of Surgery
Director of Robotic Thoracic Surgery
Yale School of Medicine
Smilow Cancer Hospital Thoracic Oncology Program   

Board Certified General Surgeon (ACS) and Thoracic Surgeon (ABTS).  A skilled surgeon, his practice includes minimally invasive and open management for diseases of the esophagus, lung, mediastinum, chest wall, thoracic outlet, and diaphragm.

Image

Michael M. Conway MD

Member, Lumeda Scientific Advisory Board         

President of Medical Staff, Chief of the Pulmonary Division, Director of Patient Care Information System  Hartford Hospital (Retired)

Pulmonary Disease and Internal Medicine specialist, Board Certification American Board of Internal Medicine, Board Certification Pulmonary Disease, expertise in diagnosing and staging respiratory cancers and associated standards of care and treatment options.

Image

Dr. Sandra Gollnick PhD 

Tumor Immunologist                 

Director of Faculty Development Director, Photodynamic Therapy Center  Distinguished Professor, Dept. of Immunology  Roswell Park Comprehensive Cancer Center (Retired)                     

Internationally recognized expert in PDT induced anti-tumor effects, with a focus on developing clinical protocols for treatment of head and neck and lung cancers for enhanced tumor control, including control of metastases, with minimal effect of quality of life.

Image

Trevor W. MacDougall

Founder and Technical Advisor


Senior Director of Engineering, EFFECT Photonics
Maynard, MA USA                                                   

35+ years photonics industry experience in lead technical roles at 3M, CiDRA Corporation, Weatherford International, and co-founder of QOREX. 55 patents, 20 publications, and co-author of Fiber Optic Sensors: Fundamentals and Applications 4th Edition (SPIE 2015).

Image

Jason Pesterfield

Independent Board Member, Strategic Advisor           

President & CEO Elucent Medical                            Eden Prairie, MN USA

Former CEO of Optellum and Veran Medical- a provider of a navigation platform for detection and treatment of lung cancer acquired by Olympus Medical. Expertise in developing innovative commercialization strategies to launch new medical technologies in the lung cancer space.

Image

Paul E. Sanders

Founder and Advisor- Clinical Development          

President, Strategies & Analysis LLC               Guilford, CT USA 

40+ years photonics industry experience in technical and senior management roles at 3M, JDS Uniphase, and Weatherford International. Co-founder of QOREX- a leader in harsh environment fiber optic sensing systems. 41 patents, over 40 technical publications and trade articles.

PARTNERS

We work in close partnership with our institutional and pharmaceutical partners in clinical development of our therapeutic platform.  We leverage the expertise of established firms in support of our regulatory affairs, reimbursement strategy and growth of our IP portfolio.

 

Image
Image
Image
Image

INVESTORS

Image
Image